Extended Data Fig. 9: Validation of the survival impact of PPP2R1A mutations in clinical cohorts of other cancer types. | Nature

Extended Data Fig. 9: Validation of the survival impact of PPP2R1A mutations in clinical cohorts of other cancer types.

From: PPP2R1A mutations portend improved survival after cancer immunotherapy

Extended Data Fig. 9: Validation of the survival impact of PPP2R1A mutations in clinical cohorts of other cancer types.

a-b. Kaplan-Meier survival analysis of the impact of PPP2R1A mutation status on the OS of patients receiving immunotherapy (a) or other therapies (b) from large pan-cancer cohorts (Samstein et al., 2019; Zehir et al., 2017). c. Kaplan-Meier survival analysis of the impact of PPP2R1A mutation status on the PFS of NSCLC patients treated with ICB therapies (Hellmann et al., 2019). d. Kaplan-Meier survival analysis of the impact of PPP2R1A mutation status on the OS of melanoma patients treated with ICB therapies. For panels a-d, P values were calculated using two-sided log-rank tests.

Back to article page